The Conversation (0)
Bio-Matrix Scientific Group Inc. (OTCQB:BMSN) announced that Regen BioPharma Inc., its 100-percent-owned subsidiary, has begun a preclinical study on its HemaXellerate product, which is aimed at using endothelial cells to restore blood production in patients with hematological conditions. Cascade Life Sciences Inc. will be conducting the research on HemaXellerate on Regen’s behalf.
Bio-Matrix Scientific Group Inc. (OTCQB:BMSN) announced that Regen BioPharma Inc., its 100-percent-owned subsidiary, has begun a preclinical study on its HemaXellerate product, which is aimed at using endothelial cells to restore blood production in patients with hematological conditions. Cascade Life Sciences Inc. will be conducting the research on HemaXellerate on Regen’s behalf.
As quoted in the press release:
The results of Regen’s study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
J. Christopher Mizer, Regen’s president, commented:
Unlike current approaches of administering pharmaceuticals our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally.
Click here to read the full Bio-Matrix Scientific Group Inc. (OTCQB:BMSN) press release.Â
